DAB2IP and prostate cancer: In prostate cancer, DAB2IP prevents EMT induced by IFN-γ treatment by dampening the JAK/STAT1 response and preventing upregulation of IFIT5, a gene involved in XRN1-mediated turnover of the anti-metastatic microRNA miR-363 [18].